Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with RelapsedRefractory Lymphoid Malignancies
PRLD Stock | USD 0.91 0.02 2.25% |
About 58% of all Prelude Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Prelude Therapeutics suggests that some traders are interested. The current market sentiment, together with Prelude Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prelude Therapeutics stock news signals to limit their universe of possible portfolio assets.
Prelude |
PRT2527 demonstrated activity across a range of relapsedrefractory lymphoid malignancies, including patients who received prior CAR-T therapy ...
Read at globenewswire.com
Prelude Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Prelude Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Prelude Therapeutics Fundamental Analysis
We analyze Prelude Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Prelude Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Prelude Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prelude Therapeutics stock to make a market-neutral strategy. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with similar companies.
Peers
Prelude Therapeutics Related Equities
MLYS | Mineralys Therapeutics, | 1.56 | ||||
PHVS | Pharvaris | 0.05 | ||||
GLUE | Monte Rosa | 0.13 | ||||
ANTX | AN2 Therapeutics | 0.74 | ||||
MOLN | Molecular Partners | 1.87 | ||||
NRIX | Nurix Therapeutics | 4.44 | ||||
RVMD | Revolution Medicines | 4.85 | ||||
PEPG | PepGen | 5.58 | ||||
STTK | Shattuck Labs | 6.09 | ||||
BDTX | Black Diamond | 6.40 | ||||
KYMR | Kymera Therapeutics | 7.66 | ||||
RZLT | Rezolute | 8.11 | ||||
PASG | Passage Bio | 8.96 | ||||
CCCC | C4 Therapeutics | 9.63 | ||||
FHTX | Foghorn Therapeutics | 10.89 |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |